Exact Sciences has a portfolio of over 110 issued patents and over 60 pending patent applications in the US, Europe, Japan, Canada, Australia and elsewhere.
Jeffrey Luber, president of Exact Sciences, said: “We are very pleased with the decision of the EPO in support of our European patent, one of the many patents in our broad intellectual property portfolio that covers a wide range of technologies relating to cancer detection. We believe this ruling is further evidence of the strength of our patent position and our commitment to vigorously defending and enforcing our intellectual property rights worldwide.”